The Canadian Students for Sensible Drug Policy (CSSDP) of Toronto are going to be holding their fourth annual Mapping the Mind with Mushrooms conference on September 22, 2018, 9:00 AM - 6:00 PM.
The annual conference aims to bring the ongoing psychedelic research renaissance to the general public. Over the last 20 years, psilocybin, LSD, MDMA, and more have returned to scientific laboratories and have been informing neuroscience and therapeutic practice at an unprecedented rate. Psychologists, philosophers and mycologists address the current findings and implications of psychedelic mushrooms and more.
Hosted at the University of Toronto
Earth Science Centre
5 Bancroft Avenue
Learn, converse and connect about the healing potentials of psychedelic medicines (including Ketamine, MDMA, Ayahuasca, and Psilocybin) at this year's Psychedelic Psychotherapy Forum 2018: The Unfolding Promise. Enjoy two full days of Forum, and post-forum weekend workshops, in Victoria, BC, Canada. Participants include psychologists, psychiatrists/doctors, therapists/counsellors, social workers, integrated health professionals, and anyone who is curious about new directions in psychotherapy.
Dr. Robin Carhart-Harris is presenting the keynote address on psychedelics and the "entropic" brain. He will be joined by Joe Tafur, MD, Philip Wolfson, MD, Anthony Bossis, PhD, Rachel Harris, PhD, and many others.
Registration is now open. Previous Forums sold out, so register early!
Visit the Psychedelic Psychotherapy website for registration and details.
MAPS Canada is proud to be a main sponsor of the Forum.
We are seeking volunteers for a research study, who are at least 18 years old and have been diagnosed with PTSD. Must be in good physical health to participate.
We are studying an investigational drug (MDMA) used in combination with psychotherapy. The study takes place in Vancouver, BC, Canada.
The full study title is Long Term Follow-up to An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder - Canada